Vast Therapeutics Announces Funding from Cystic Fibrosis Foundation for Further Development of BIOC51
Vast Therapeutics (formerly Novoclem) Announces Results Showing Eradication of all In Vitro Tested Multi-Drug Resistant Bacteria and a 99% Reduction of Nontuberculous Mycobacteria (NTM) in Animal Model.
Anne Whitaker keynote speaker for Novoclem Therapeutics, Inc. at CED Life Science Conference on February 27-28, 2018.
Novoclem announces CEO Anne Whitaker to present at the BIO CEO & Investor Annual Conference on Monday February 12th, 2018
Novoclem announces CEO Anne Whitaker to present at the Biotech Showcase™ Annual Conference on Wednesday, January 10, 2018